Presidential candidate Hillary Clinton brought down the hammer on drug makers last week, promising to “take on” drug companies that charge Americans the highest prices in the world for drugs developed in part with government funds.
The Trump Presidential campaign rolled out its first major television ad last week, aimed at voters in Florida, Ohio, North Carolina and Pennsylvania. For Social Security experts and advocates, it wasn’t worth waiting for.
Aetna’s announcement this week that it was pulling out of most of the states where it was serving the Obamacare individual exchanges was a head-scratcher; after all, just three months earlier, CEO Mark Bertolini was calling its participation in the market “a good investment,” despite near-term losses.
We wrote last week about the absurdity of Donald Trump’s proposal to repeal the estate tax— excuse us, the “death tax,” as it’s dubbed by critics who think it’s better to fool people via linguistics than by making substantive arguments.
Mylan, the profiteering, tax-dodging drug company currently taking immense heat for jacking up the price of its Epipen by 500%, announced Thursday that it will help more patients cover their soaring out-of-pocket costs for the allergy drug device.
The pharmaceutical company Mylan has been taking on a boatload of vituperation — and rightfully so— for jacking up the price of its lifesaving EpiPen injector, which reverses allergic reactions, by 500%.
Call it logrolling or one hand washing the other, a generally recognized fact in Washington is that if you want something for your district, it pays to agree to the same thing for another guy’s district.
Visitors to the website of StemGenex , a La Jolla medical group, could be forgiven for thinking that the answer to their prayers is finally at hand. Pitched at sufferers of lung disease, Parkinson’s, autoimmune conditions such as multiple sclerosis and rheumatoid arthritis and even Alzheimer’s, the site offers treatments based on injecting patients with stem cells drawn from their own body fat.
Big private insurance companies bailing out of a government-sponsored healthcare program, complaining about financial losses. Hundreds of thousands of customers lose their health plans. Terminations are especially severe in rural counties, leaving virtually no competition. Total enrollment drops.